JLM070
/ Jecho Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 02, 2026
A novel PD-L1-directed 4-1BB ligand fusion protein, JLM070, demonstrates potent antitumor activity and a favorable safety profile in preclinical models
(SITC 2026)
- No abstract available
Preclinical • Oncology • PD-L1
1 to 1
Of
1
Go to page
1